Compare TRDA & ELMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRDA | ELMD |
|---|---|---|
| Founded | 2016 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.3M | 326.9M |
| IPO Year | 2021 | 2010 |
| Metric | TRDA | ELMD |
|---|---|---|
| Price | $6.21 | $28.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $21.00 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 290.0K | 91.6K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 52.94 |
| EPS | N/A | ★ 1.30 |
| Revenue | $25,421,000.00 | ★ $54,716,000.00 |
| Revenue This Year | $39.97 | $15.59 |
| Revenue Next Year | $50.80 | $11.51 |
| P/E Ratio | ★ N/A | $21.45 |
| Revenue Growth | N/A | ★ 13.83 |
| 52 Week Low | $5.56 | $23.01 |
| 52 Week High | $16.45 | $47.40 |
| Indicator | TRDA | ELMD |
|---|---|---|
| Relative Strength Index (RSI) | 36.70 | 35.55 |
| Support Level | $5.71 | $27.14 |
| Resistance Level | $7.89 | $29.57 |
| Average True Range (ATR) | 0.39 | 0.87 |
| MACD | -0.09 | 0.63 |
| Stochastic Oscillator | 13.85 | 83.07 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.